Ponesimod

CHEMBL1096146 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

461.0 g/mol

LogP

4.6

Phase

4

Used to reduce the frequency of relapses and slow the progression of disability in adults with relapsing forms of multiple sclerosis by trapping certain immune cells in lymph nodes, preventing them from reaching the brain and spinal cord where they cause damage. It is taken as a daily tablet with a gradual dose-escalation schedule to minimize heart rate effects.

Peso molecular

461,0000 g/mol

LogP

4,60

TPSA

108,00 Å²

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Psoriasis Multiple Sclerosis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCC/N=C1\S/C(=C\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C

InChI

InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23-/t17-/m1/s1

Molecular Formula

C23H25ClN2O4S

HBD / HBA

2 / 6

Enlaces Rotables

8

Átomos Pesados

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

Used to reduce the frequency of relapses and slow the progression of disability in adults with relapsing forms of multiple sclerosis by trapping certain immune cells in lymph nodes, preventing them from reaching the brain and spinal cord where they cause damage. It is taken as a daily tablet with a gradual dose-escalation schedule to minimize heart rate effects.

Yes, Ponesimod is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1096146. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11363176. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

¿Busca información accesible para el paciente?

Ponesimod en PillFYI

Estructura

Datos Rápidos

Fórmula: C23H25ClN2O4S
Sinónimos: 1

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.